

Global Cancer Monoclonal Antibodies Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G866321E82AEN.html>

Date: November 2017

Pages: 210

Price: US\$ 4,400.00 (Single User License)

ID: G866321E82AEN

Abstracts

Global Cancer Monoclonal Antibodies Market:

Global cancer monoclonal antibodies market estimated to be valued US\$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for cancer monoclonal antibodies is projected to reach US\$ XX Mn by 2023.

A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs.

The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high

cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.

Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel

Base on application, cancer monoclonal antibodies market is segmented into

Breast Cancer

Blood Cancer

Liver Cancer

Brain cancer

Colorectal Cancer

Others

Based on type of antibody, cancer monoclonal antibodies market is segmented into

Murine Antibodies

Humanized Antibodies

Chimeric Antibodies

Based on conjugation, cancer monoclonal antibodies market is segmented into

Immunocytokines

Immunoliposome

Radioimmunotherapy

Antibody Directed Enzyme Prodrug Therapy(ADEPT)

Based on distribution channel, cancer monoclonal antibodies market segmented into

Hospital Pharmacies

Retail Pharmacies

Clinics

Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.

Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.

Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.

In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma

In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology's tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET INTRODUCTION

2.1. Global Cancer Monoclonal Antibodies Market– Taxonomy

2.2. Global Cancer Monoclonal Antibodies Market–Definitions

2.2.1. Application

2.2.2. Distribution Channel

3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cancer Monoclonal Antibodies Market Dynamics – Factors Impact Analysis

3.6. Global Cancer Monoclonal Antibodies Market– Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.7. Global Cancer Monoclonal Antibodies Market– Recent Product Launches

4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Breast Cancer

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Blood Cancer

- 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis
- 5.3. Liver Cancer
 - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.3.3. Market Opportunity Analysis
- 5.4. Brain cancer
 - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.4.3. Market Opportunity Analysis
- 5.5. Colorectal Cancer
 - 5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.5.3. Market Opportunity Analysis
- 5.6. Others
 - 5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.6.3. Market Opportunity Analysis

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY TYPE OF ANTIBODY, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Murine Antibodies
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.1.3. Market Opportunity Analysis
- 6.2. Humanized Antibodies
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.2.3. Market Opportunity Analysis
- 6.3. Chimeric Antibodies
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.3.3. Market Opportunity Analysis

7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY CONJUGATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Immunocytokines

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Immunoliposome

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Radioimmunotherapy

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Retail Pharmacies

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Online Pharmacies

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

- 9.1.3. Market Opportunity Analysis
- 9.2. Europe
 - 9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 9.2.3. Market Opportunity Analysis
- 9.3. Asia-Pacific
 - 9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 9.3.3. Market Opportunity Analysis
- 9.4. Latin America
 - 9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 9.4.3. Market Opportunity Analysis
- 9.5. Middle East and Africa
 - 9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 9.5.3. Market Opportunity Analysis
- 9.6. Global Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 10.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 10.1.1.1. Breast Cancer
 - 10.1.1.2. Blood Cancer
 - 10.1.1.3. Liver Cancer
 - 10.1.1.4. Brain cancer
 - 10.1.1.5. Colorectal Cancer
 - 10.1.1.6. Others
- 10.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.2.1. Murine Antibodies
 - 10.1.2.2. Humanized Antibodies
 - 10.1.2.3. Chimeric Antibodies
- 10.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.1.3.1. Immunocytokines
- 10.1.3.2. Immunoliposome
- 10.1.3.3. Radioimmunotherapy
- 10.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
- 10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.4.1. Hospital Pharmacies
 - 10.1.4.2. Retail Pharmacies
 - 10.1.4.3. Online Pharmacies
- 10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
 - 10.1.5.1. U.S.
 - 10.1.5.2. Canada
- 10.1.6. North America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
- 10.1.7. North America Cancer Monoclonal Antibodies Market Dynamics – Trends

11. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 11.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 11.1.1.1. Breast Cancer
 - 11.1.1.2. Blood Cancer
 - 11.1.1.3. Liver Cancer
 - 11.1.1.4. Brain cancer
 - 11.1.1.5. Colorectal Cancer
 - 11.1.1.6. Others
- 11.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.2.1. Murine Antibodies
 - 11.1.2.2. Humanized Antibodies
 - 11.1.2.3. Chimeric Antibodies
- 11.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.3.1. Immunocytokines
 - 11.1.3.2. Immunoliposome
 - 11.1.3.3. Radioimmunotherapy

- 11.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
- 11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.4.1. Hospital Pharmacies
 - 11.1.4.2. Retail Pharmacies
 - 11.1.4.3. Online Pharmacies
- 11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.5.1. Germany
 - 11.1.5.2. UK
 - 11.1.5.3. France
 - 11.1.5.4. Spain
 - 11.1.5.5. Italy
 - 11.1.5.6. Russia
 - 11.1.5.7. Poland
 - 11.1.5.8. Rest of Europe
- 11.1.6. Europe Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
- 11.1.7. Europe Cancer Monoclonal Antibodies Market Dynamics – Trends

12. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 12.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 12.1.1.1. Breast Cancer
 - 12.1.1.2. Blood Cancer
 - 12.1.1.3. Liver Cancer
 - 12.1.1.4. Brain cancer
 - 12.1.1.5. Colorectal Cancer
 - 12.1.1.6. Others
- 12.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.2.1. Murine Antibodies
 - 12.1.2.2. Humanized Antibodies
 - 12.1.2.3. Chimeric Antibodies
- 12.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 12.1.3.1. Immunocytokines
- 12.1.3.2. Immunoliposome
- 12.1.3.3. Radioimmunotherapy
- 12.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
- 12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.4.1. Hospital Pharmacies
 - 12.1.4.2. Retail Pharmacies
 - 12.1.4.3. Online Pharmacies
- 12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 12.1.5.1. Japan
 - 12.1.5.2. China
 - 12.1.5.3. India
 - 12.1.5.4. ASEAN
 - 12.1.5.5. Australia & New Zealand
 - 12.1.5.6. Rest of Asia-Pacific
- 12.1.6. Asia-Pacific Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
- 12.1.7. Asia-Pacific Cancer Monoclonal Antibodies Market Dynamics – Trends

13. LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 13.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.1.1.1. Breast Cancer
 - 13.1.1.2. Blood Cancer
 - 13.1.1.3. Liver Cancer
 - 13.1.1.4. Brain cancer
 - 13.1.1.5. Colorectal Cancer
 - 13.1.1.6. Others
- 13.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.2.1. Murine Antibodies
 - 13.1.2.2. Humanized Antibodies
 - 13.1.2.3. Chimeric Antibodies

13.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Immunocytokines

13.1.3.2. Immunoliposome

13.1.3.3. Radioimmunotherapy

13.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)

13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.4.1. Hospital Pharmacies

13.1.4.2. Retail Pharmacies

13.1.4.3. Online Pharmacies

13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.5.1. Brazil

13.1.5.2. Mexico

13.1.5.3. Argentina

13.1.5.4. Venezuela

13.1.5.5. Rest of Latin America

13.1.6. Latin America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023

13.1.7. Latin America Cancer Monoclonal Antibodies Market Dynamics – Trends

14. MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.1.1. Breast Cancer

14.1.1.2. Blood Cancer

14.1.1.3. Liver Cancer

14.1.1.4. Brain cancer

14.1.1.5. Colorectal Cancer

14.1.1.6. Others

14.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.2.1. Murine Antibodies

14.1.2.2. Humanized Antibodies

14.1.2.3. Chimeric Antibodies

14.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.3.1. Immunocytokines

14.1.3.2. Immunoliposome

14.1.3.3. Radioimmunotherapy

14.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)

14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.4.1. Hospital Pharmacies

14.1.4.2. Retail Pharmacies

14.1.4.3. Online Pharmacies

14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.5.1. Gulf Cooperation Council (GCC) Countries

14.1.5.2. Israel

14.1.5.3. South Africa

14.1.5.4. Rest of MEA

14.1.6. MEA Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023

14.1.7. MEA Cancer Monoclonal Antibodies Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. Merck & Co. Inc. (U.S.)

15.2.2. F. Hoffmann-La Roche AG (Switzerland)

15.2.3. Spectrum Pharmaceuticals (U.S.)

15.2.4. Eli Lilly and Company (U.S.)

15.2.5. Amgen Inc. (U.S.)

15.2.6. Bristol-Meyer Squibb (U.S.)

15.2.7. Sanofi (France)

15.2.8. AstraZeneca (U.K.)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Cancer Monoclonal Antibodies Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G866321E82AEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G866321E82AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

